COMMUNIQUÉS West-GlobeNewswire

New York Plastic Surgical Group Expands to New Jersey with New Englewood Location
12/09/2025
Garden City, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group (NYPS Group), one of the nation’s longest-standing plastic surgery practices, is proud to announce its expansion into New Jersey with [...]
Les actionnaires de Theratechnologies approuvent le plan d’arrangement proposé visant l’acquisition de la Société par Future Pak
12/09/2025
MONTRÉAL, 12 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, est heureuse d’ [...]
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
12/09/2025
MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“ Theratechnologies ” or the “ Company ”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its [...]
Virbac : Half-yearly financial report 2025
12/09/2025
Please find attached 2025 Half-yearly financial report of Virbac Attachment Half-Yearly Financial Report_2025
Virbac : Rapport financier semestriel 2025
12/09/2025
Ci-joint le rapport financier semestriel 2025 de Virbac Pièce jointe Rapport financier semestriel_2025
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2025
12/09/2025
Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier semestriel au 30 juin 2025. Le rapport financier semestriel peut également être consulté [...]
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
12/09/2025
The Group released and filed its 2025 half-year financial report with the French “Autorité des marchés financiers”. The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “ [...]
VIRBAC: résultats semestriels 2025
12/09/2025
Une solide croissance du chiffre d'affaires du premier semestre 2025 de +5,6% à taux de change et périmètre constants Résultat opérationnel courant ajusté 2 de 18,3% en ratio du chiffre d’affaires en ligne avec nos [...]
Virbac: 2025 Half-year results
12/09/2025
Solid revenue growth in the first half of 2025 of +5.6% at constant exchange rates and scope Adjusted recurring operating income² of 18.3% as a ratio to revenue, in line with our expectations Down compared to 2024 due [...]
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
12/09/2025
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “ [...]
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
12/09/2025
AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing transformative oncology and [...]
Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
12/09/2025
KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green Med” or the “Company”), a company engaged in diversified industries, today announced that [...]
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
12/09/2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that [...]
Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
12/09/2025
GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration GAL-101 effectively crosses the blood-brain barrier, supporting further development in Alzheimer’s disease A [...]
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
12/09/2025
Ra’anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging [...]
Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
12/09/2025
MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently [...]
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
12/09/2025
ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, [...]
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
12/09/2025
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for [...]
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
12/09/2025
BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s [...]

Pages